News

The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant

Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication trend led by Ozempic, Novo Nordisk A/S (NYSE: NVO)

The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused

Johnson & Johnson (NYSE: JNJ),  Gilead Sciences Inc. (NYSE: GILD) and Bristol Myers Squibb Co. (NYSE: BMY) are among healthcare sector dividend-payers trading at low valuations relative to their

Welcome to the jungle. Today's stock market is not the one you inherited from your parents or even your grandparents. In prior generations, information took a bit longer to spread across sectors

Aftermarket auto parts retailer Advanced Auto Parts Inc. (NYSE: AAP) has dramatically underperformed its Auto/Tires/Trucks sector peers. Its shares are trading down 66.8% year-to-date (YTD)

Stocks that crush their earnings estimates are supposed to go up. However, that's not always the case. Every earnings season, regardless of sector or industry, has its share of stocks that report

In recent years, AI has gone from a niche industry housed mostly in research labs, academia, and large companies like Google to dominating the news cycle and driving incredible growth and value

Marketbeat's stock screening tools are a wealth of investment ideas, including the 52-week low list. Stocks trading at 52-week lows often provide oversold value ready to spring back, given the

The World Series champion Texas Rangers recently paid nice dividends for sports bettors. For stock investors, there's a different, more predictable group of dividend payers worth betting on — the

Shares of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a

GSK (NYSE: GSK) is not immune to the patent cliff faced by the pharmaceutical industry, but it is about as well prepared as it can be. The company faces a smaller impact than others, has years to

Pharmaceutical stocks aren't having quite the banner year they've had in the past. Notably, two large pharmaceutical companies recently plunged to 52-week lows on their earnings results. Many

Because earnings guidance is a company's best effort to forecast its earnings, it is a leading cause of share price movement. However, simply raising or lowering guidance is not enough to move a

Shares of AbbVie Inc. (NYSE: ABBV) have been under pressure for nearly two years because of mounting fears about the patent cliff. The patent cliff impacted the company’s results but has done

After a stellar first half to the year, especially when compared to last year's bloodbath, the S&P 500 index has been trending down since August. Friday was its third big down day in a row, and by

Abbott Laboratories (NYSE: ABT) share price has trended lower for nearly 2 years, but that trend is over. The impact of COVID on sales and the post-COVID letdown were cause enough for the market

Over the last several months, many sectors, industries, and the overall market have come under pressure and experienced significant outflows and waves of selling. 

During this period, over the

While the direction of the stock markets is unpredictable, the growth of the aging population is entirely predictable. Along with an aging population come additional healthcare, beauty and

It’s not often that you see a company whose main product comes with a price tag of over $2 million, but that’s the case with biotechs BioMarin Pharmaceutical (NASDAQ: BMRN) and Sarepta

If you want to get an isolated view of a constructive base taking shape in a strong stock, take a look at the Argenix SE (NASDAQ: ARGX) chart. 

The stock gapped up nearly 28% on July 17, after

If you’re looking for a sector that’s on sale, look to healthcare. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) is down 2.50% in the past month, lagging the S&P 500. 

The top